Curated News
By: NewsRamp Editorial Staff
March 28, 2025
United Health Products Updates FDA and OTC Markets Applications
TLDR
- UHP's CelluSTAT Hemostatic Gauze has met safety requirements for a Class III device, potentially positioning the company for increased market competitiveness.
- FDA requested additional tests for UHP's IDE application, confirming sterility and biocompatibility of the product, essential for commencing clinical study enrollment.
- UHP's natural hemostatic agent aims to improve patient outcomes by controlling bleeding, seeking approval to access the surgical market for better medical care.
- UHP's innovative CelluSTAT Hemostatic Gauze offers a promising solution to manage mild to moderate bleeding, potentially revolutionizing medical treatment methods.
Impact - Why it Matters
This news matters as it highlights the progress of United Health Products in meeting FDA requirements for its hemostatic gauze product. The successful completion of sterilization and biotoxicity tests is a significant step towards accessing the human surgical market. Investors and stakeholders will be monitoring the outcome of the FDA Premarket Approval and OTCQB uplisting applications.
Summary
United Health Products, Inc. provides an update on regulatory and capital markets activities, including FDA testing results for its CelluSTAT Hemostatic Gauze. The company has submitted these results as part of its revised IDE application. Additionally, UHP has provided OTC Markets with the necessary information for an uplisting of its common shares.
Source Statement
This curated news summary relied on this press release disributed by NewMediaWire. Read the source press release here, United Health Products Updates FDA and OTC Markets Applications
